Peptide News Digest

#Endocrine-Society

2 stories

Industry · View digest

ENDO 2026 Opens in Chicago Through June 16 With 2,500 Abstracts and 7,200 Attendees Across Diabetes, Obesity, Bone, and Rare Endocrine

The Endocrine Society's annual meeting ENDO 2026 opened today at McCormick Place West in Chicago and runs through Tuesday June 16, drawing roughly 7,200 attendees and nearly 2,500 abstracts spanning diabetes, obesity, reproductive health, bone health, endocrine-disrupting chemicals, and thyroid cancer. Saturday's plenary 'Unraveling Hormonal Complexity: Genomics, Sex Differences, and Physiology' features I. Sadaf Farooqi (Cambridge) on single-cell genomics and Holly A. Ingraham (UCSF) on hormones and brain-body physiology. Peptide-anchored programs concentrated in the hypoparathyroidism (Ascendis, MBX, Entera), acromegaly (Crinetics), and oral GLP-1 (Entera EB618 preclinical) tracks; oncology-peptide tracks include OAR-targeted radioligand abstracts and copper-peptide bone-resorption work.

Research · View digest

EASO Framework US Implementation Reception — Endocrinology Society Response Awaited as First-Line GLP-1 Algorithm Lands

The EASO 2026 Nature Medicine framework published May 14, presented at ECO 2026 — formally privileging semaglutide and tirzepatide as first-line therapy across most obesity complications with differentiated complication-specific recommendations — has generated initial reception coverage. The Endocrine Society and American Diabetes Association haven't yet issued formal endorsement or counter-response statements as of May 16, though informal commentary from US endocrinologists has been broadly favorable. The framework's main US-specific gap is its silence on cost and insurance access — the algorithm assumes prescribers can choose between semaglutide and tirzepatide based on clinical indication, but US patients without diabetes face the Medicare Part D weight-loss-only exclusion. The Medicare GLP-1 Bridge launching July 1, 2026 partly addresses that gap; broader integration awaits CMS rulemaking. ADA 2026 Scientific Sessions in New Orleans June 5-8 will be the next inflection point for guideline alignment between US and EASO positions.